Study for people already taking ONO-4538
Treatments studied
Part of Cancer clinical trials.
This trial is for people who are already being treated with ONO-4538 (either alone or with other treatments) and can continue into an “extension/rollover” study. It checks how well ONO-4538 continues to work and is used safely over more time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are currently taking ONO-4538 either by itself or along with other approved trial treatments.
- You are already considered eligible for ONO-4538 treatment in your current study, including if the study doctor thinks you’re benefiting.
- You can understand the study and give informed consent (for example, no severe memory problems that prevent consent).
- The study doctor must agree that the study is appropriate for you based on your overall situation.
- You must be able to continue participation as decided by your treating study team.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, ONO-4538, in people with rhabdoid tumors that have come back or spread and cannot be removed with surgery. It is for those who have already tried at least one chemotherapy treatment that did not work or caused side effects.
This trial tests a new drug (ONO-4578) combined with standard chemotherapy and immunotherapy for people with advanced colorectal cancer that has not been treated before and has a specific marker called PD-L1. The goal is to see if this combination works better than the usual treatment.
This trial tests an experimental drug called ONC-783 for people with advanced pancreatic, ovarian, colorectal, or breast cancer. The goal is to see if the drug is safe, how it works in the body, and whether it can help shrink tumors.
This trial tests a new drug (ONO-4578) combined with the usual immunotherapy (nivolumab) and chemotherapy for stomach cancer that has not been treated before. It aims to see if adding this drug helps shrink tumors or slows disease growth better than placebo.
This trial tests a new drug called SIM0508, given alone or with another drug (olaparib), in people with advanced ovarian, prostate, breast, or pancreatic cancer. The goal is to see if it is safe and effective.
This is a “rollover” study for people who were already taking a Roche (or Genentech) cancer study medicine. It checks whether continuing the same study treatment (when commercial options aren’t available) can keep helping you.
Hear when a new Pan-tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.